6.84
-0.31(-4.34%)
Currency In USD
| Previous Close | 7.15 |
| Open | 7.08 |
| Day High | 7.3 |
| Day Low | 6.77 |
| 52-Week High | 7.82 |
| 52-Week Low | 2.77 |
| Volume | 1.12M |
| Average Volume | 1.03M |
| Market Cap | 263.95M |
| PE | -4.92 |
| EPS | -1.39 |
| Moving Average 50 Days | 5.91 |
| Moving Average 200 Days | 4.4 |
| Change | -0.31 |
If you invested $1000 in Protara Therapeutics, Inc. (TARA) 10 years ago, it would be worth $28.45 as of February 21, 2026 at a share price of $6.84. Whereas If you bought $1000 worth of Protara Therapeutics, Inc. (TARA) shares 5 years ago, it would be worth $330.43 as of February 21, 2026 at a share price of $6.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
GlobeNewswire Inc.
Jan 22, 2026 1:00 PM GMT
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the co
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway i